Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.

Novartis revealed it is acquiring California-based biotech UF Startup Kate Therapeutics, a move that “complements” the pharma’s push to deliver innovative treatments for neuromuscular disorders and deepen its expertise in gene therapy.

Read more about Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030.